Korea 2023 Review: R&D Potential Shines Through Despite Challenges
ADCs, TPD Come Into Focus
Despite some disappointments, the South Korean pharma industry showed mostly resilient R&D activity in 2023 amid robust efforts to secure technologies and assets in new modalities such as ADCs and TPD to better compete with global players.
